SK279285B6 - Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin - Google Patents

Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin Download PDF

Info

Publication number
SK279285B6
SK279285B6 SK1306-92A SK130692A SK279285B6 SK 279285 B6 SK279285 B6 SK 279285B6 SK 130692 A SK130692 A SK 130692A SK 279285 B6 SK279285 B6 SK 279285B6
Authority
SK
Slovakia
Prior art keywords
dementia
improvement
iii
symptoms
compound
Prior art date
Application number
SK1306-92A
Other languages
English (en)
Slovak (sk)
Inventor
Eiichi Otomo
Yoshiyuki Takasu
Tadashi Shiotani
Kazuo Hasegawa
Akira Honma
Original Assignee
Daiichi Pharmaceutical Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co. filed Critical Daiichi Pharmaceutical Co.
Publication of SK279285B6 publication Critical patent/SK279285B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1306-92A 1991-05-02 1992-04-29 Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin SK279285B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22981891 1991-05-02
JP22981991 1991-05-02

Publications (1)

Publication Number Publication Date
SK279285B6 true SK279285B6 (sk) 1998-09-09

Family

ID=26529012

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1306-92A SK279285B6 (sk) 1991-05-02 1992-04-29 Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin

Country Status (21)

Country Link
US (1) US5886023A (cs)
EP (1) EP0515866B1 (cs)
KR (1) KR100310590B1 (cs)
AT (1) ATE203402T1 (cs)
AU (2) AU1595492A (cs)
CA (1) CA2067614C (cs)
CZ (1) CZ281170B6 (cs)
DE (1) DE69231955T2 (cs)
DK (1) DK0515866T3 (cs)
ES (1) ES2160097T3 (cs)
GR (1) GR3036970T3 (cs)
HU (1) HU224689B1 (cs)
IE (1) IE921377A1 (cs)
IL (1) IL101738A (cs)
MX (1) MX9202058A (cs)
NO (1) NO312813B1 (cs)
PT (1) PT515866E (cs)
RU (1) RU2070042C1 (cs)
SG (1) SG49650A1 (cs)
SK (1) SK279285B6 (cs)
TW (1) TW199096B (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727482B2 (en) * 1996-10-01 2000-12-14 Daiichi Pharmaceutical Co., Ltd. Mitochondrial membrane stabilizer
EP1020189B1 (en) 1997-07-15 2004-05-12 Daiichi Pharmaceutical Co., Ltd. Nefiracetam for prevention and treatment of amnesia caused by propofol
IT1312107B1 (it) * 1999-05-14 2002-04-04 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
EP1180366A1 (en) * 1999-05-31 2002-02-20 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6423739B1 (en) 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6348489B1 (en) 2000-04-11 2002-02-19 Daiichi Pharmaceutical Co., Ltd. Method of treating traumatic brain injury and other neuronal disorders
KR100823668B1 (ko) * 2000-12-28 2008-04-21 해밀턴 파마슈티컬스 인코포레이티드 신경성 통증 치료 및 예방약
CA2457982C (en) * 2001-08-22 2009-11-03 Daiichi Pharmaceutical Co., Ltd. Use of nefiracetam for treating neurodegeneration
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
US7972633B2 (en) * 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
RU2327480C1 (ru) * 2007-05-23 2008-06-27 Виктор Иванович Рощин Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом
DK3260118T3 (da) * 2008-10-16 2021-04-19 Univ Johns Hopkins Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
EA202092673A3 (ru) * 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
IT1141287B (it) * 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
US4385053A (en) * 1981-03-11 1983-05-24 Barry Reisberg Treatment for human memory impairment associated with aging
JPH0699307B2 (ja) * 1987-08-20 1994-12-07 キッセイ薬品工業株式会社 抗痴呆剤
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti

Also Published As

Publication number Publication date
NO921724L (no) 1992-11-03
EP0515866A1 (en) 1992-12-02
ATE203402T1 (de) 2001-08-15
KR100310590B1 (ko) 2001-12-28
PT515866E (pt) 2001-11-30
ES2160097T3 (es) 2001-11-01
CA2067614A1 (en) 1992-11-03
AU3774595A (en) 1996-03-07
HUT62790A (en) 1993-06-28
US5886023A (en) 1999-03-23
KR920021143A (ko) 1992-12-18
DE69231955D1 (de) 2001-08-30
AU697936B2 (en) 1998-10-22
HK1002153A1 (en) 1998-07-31
RU2070042C1 (ru) 1996-12-10
DK0515866T3 (da) 2001-09-24
IL101738A0 (en) 1992-12-30
CA2067614C (en) 2002-07-30
NO312813B1 (no) 2002-07-08
NO921724D0 (no) 1992-04-30
AU1595492A (en) 1992-11-05
HU224689B1 (hu) 2005-12-28
TW199096B (cs) 1993-02-01
EP0515866B1 (en) 2001-07-25
DE69231955T2 (de) 2002-04-04
GR3036970T3 (en) 2002-01-31
HU9201477D0 (en) 1992-07-28
MX9202058A (es) 1993-03-01
SG49650A1 (en) 1998-06-15
CS130692A3 (en) 1992-11-18
CZ281170B6 (cs) 1996-07-17
IL101738A (en) 1999-01-26
IE921377A1 (en) 1992-11-04

Similar Documents

Publication Publication Date Title
SK279285B6 (sk) Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
Kassan et al. Clinical manifestations and early diagnosis of Sjögren syndrome
Myers et al. Late onset of Huntington's disease.
Thanvi et al. Update on myasthenia gravis
IT8249698A1 (it) Preparato farmaceutico contenente un sale di deferossammina per il trattamento di malattia di alzheimer
CN105832733A (zh) 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途
Sydenstricker et al. The effect of nicotinic acid in stupor, lethargy and various other psychiatric disorders
IE83506B1 (en) Use of N-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamide for the treatment of dementia
US20250017946A1 (en) Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases
Jablonski Jablonski's dictionary of medical acronyms & abbreviations
Greenblatt et al. Physiologic changes in old age: relation to altered drug disposition
WO2022219637A1 (en) Treatment of prodromal huntington disease
Camacho et al. Modafinil for social phobia and amphetamine dependence
Whorwell et al. Respiratory function in rheumatoid arthritis
Ferri et al. Agrypnia excitata in a patient with progeroid short stature and pigmented Nevi (Mulvihill‐Smith syndrome)
Kovalenko et al. Use of a neurometabolism-targeting drug in prevention of postoperative cognitive dysfunction
Akshaya et al. A survey study of gender-related anxiety and fear on dental care among the patients visiting Saveetha Dental College and Hospital.
US7479506B2 (en) Agent or method for treating severe aphasia in cerebrovascular accident chronic stage
JP4120713B2 (ja) 多発性硬化症治療剤
EP1698622A1 (en) Agent or method for treatment for severe aphasia in chronic-stage cerebrovascular disorder
Tetteh et al. Coexistence of relapsing polychondritis and sickle cell disease in a child
BANEN et al. Lorazepam versus Glutethimide as a Sleep‐Inducing Agent for the Geriatric Patient
EP4547256A1 (en) Methods for ameliorating cognitive impairment using bile acid derivatives
Cossío et al. Lymphopenia without neutropenia in Clozapine treatment. A review and a case report
Kraaijvanger et al. Neuroleptic malignant syndrome after overdose of haloperidol–A case report